Advanced Cancer Clinical Trial
Official title:
A Phase I Trial of Sirolimus and Cetuximab in Patients With Advanced Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the combination of sirolimus and cetuximab that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
The Study Drugs:
Cetuximab is designed to prevent or slow down the growth of cancer cells by blocking protein
on the surface of the cancer cell, called the epidermal growth factor receptor (EGFR).
Sirolimus is designed to block a protein called mTOR inside the cancer cell. This may
interfere with the growth or spread of cancer cells or possibly kill the cancer cells.
Study Drug Groups:
If you are found to be eligible to take part in this study, you will be assigned to a dose
level of cetuximab and sirolimus based on when you joined this study. Up to 9 dose levels of
cetuximab and sirolimus will be tested. Three (3) to 9 participants will be enrolled at each
dose level. The first group of participants will receive the lowest dose level. Each new
group will receive a higher dose than the group before it, if no intolerable side effects
were seen. This will continue until the highest tolerable dose of the combination of
cetuximab and sirolimus is found.
Once the highest tolerated dose of the combination of cetuximab and sirolimus is found, 2
groups of additional participants (Group 1 and Group 2, each of 14 participants) will be
enrolled and receive the study drugs at that dose level. Another 14 participants with the
non-small lung and head and neck cancer will receive the study drug at that dose level, as
well.
Study Drug Administration:
Each study "cycle" is 28 days.
Everyday, you will take sirolimus by mouth 1 time a day. You should take it at about the
same time each day with food and a cup of water.
On Days 1, 8, 15, and 22 of each cycle, you will receive cetuximab by vein over 2 hours. If
the first dose is well tolerated, you will receive the next dose over 1 hour.
Study Visits:
At every study visit, you will be asked about any current health conditions you have, drugs
you are taking, and if you have experienced any side effects.
Between Days 8 and 15 of Cycle 1, the following tests and procedures will be performed:
-If you are enrolled in a Group 2 of the highest drug combination dose, you will have a
tumor biopsy and your blood (about 1-3 tablespoons) will be drawn for pharmacodynamic (PD)
testing.
About Days 8 and 22 of Cycle 1, the following tests and procedures will be performed:
- You will have a physical exam.
- Blood (about 2 teaspoons) will be drawn for routine tests.
About Day 15 of Cycle 1, blood (about 2 teaspoons) will be drawn for routine tests.
About Day 22 of Cycles 2 and then every 1-2 cycles, the following tests and procedures will
be performed:
- You will have a physical exam.
- Blood (about 2 teaspoons) will be drawn for routine tests.
Every 4 weeks, you will have a blood (about 1 teaspoon) drawn or urine collected for
pregnancy test if you are able to become pregnant.
Every 8 weeks, you will have an x-ray, CT scan, MRI, and/or PET/CT to check the status of
the disease. The study doctor thinks it is needed, they will be performed more often.
Length of Study:
You may stay on study for as long as you are benefitting. You will be taken off study if you
experience intolerable side effects, the study doctor thinks it is in your best interest, or
the cancer gets worse.
End-of-Study Visit:
About 28 days after the last dose of study drugs, you will have an end-of-study visit. At
this visit, the following tests or procedures may be performed:
- You will have a physical exam, including measurement of your vital signs.
- Your performance status will be recorded.
- Blood (about 2 teaspoons) will be drawn for routine tests.
- If the doctor thinks it is needed, you will have an x-ray, CT, MRI, and/or PET/CT to
check the status of the disease.
This is an investigational study. Sirolimus is FDA approved and commercially available as an
anti-rejection drug for kidney transplant recipients. Cetuximab is FDA approved and
commercially available for the treatment of colorectal and head/neck cancers. The
combination of these drugs is investigational.
Up to 137 patients will take part in this study. All will be enrolled at MD Anderson.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
| Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
| Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
| Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
| Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
| Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
| Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
| Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT01901237 -
Yoga for Adolescent and Young Adult Non-Curative Cancer Patients
|
N/A |